About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker EBS · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Oct 7, 2026CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
NCT00893516 · T-cell Lymphoma
CHOP + CD4, CHOP
EBS
Emergent BioSolutions
Phase 2Terminated5Oct 2008Registry ↗
Aug 19, 2026Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
NCT05377255 · Opioid Overdose
16 mg naloxone AP003, 8 mg naloxone NARCAN Nasal Spray
EBS
Emergent BioSolutions
Phase 1Completed24May 10, 2022Registry ↗
May 12, 2026VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infec…
NCT01374984 · Complication of Smallpox Vaccination
VIGIV
EBS
Emergent BioSolutions
—Enrolling by invitation100Aug 2027Registry ↗
May 6, 2026VELOCITY: An Anthrax Vaccine Clinical Study
NCT03877926 · Anthrax
AV7909, BioThrax
EBS
Emergent BioSolutions
Phase 3Completed3,689Aug 6, 2020Registry ↗
Mar 17, 2026Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax
NCT07478471 · Infections, Bacterial
Collection of samples
EBS
Emergent BioSolutions
—Not yet recruiting10May 2030Registry ↗
Feb 6, 2026A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax…
NCT03569553 · Inhalational Anthrax
AIGIV
EBS
Emergent BioSolutions
—Not yet recruiting100Jul 2027Registry ↗
Feb 6, 2026Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With S…
NCT03569514 · Anthrax
AIGIV
EBS
Emergent BioSolutions
—Not yet recruiting10Jul 2027Registry ↗
Feb 6, 2026Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a M…
NCT02177721 · Infections, Bacterial
Sample Collection
EBS
Emergent BioSolutions
Phase 4Not yet recruiting100May 2035Registry ↗
Jan 16, 2026BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
NCT02051062 · Botulism
Blood sample collection
EBS
Emergent BioSolutions
Phase 4Enrolling by invitation10Jul 31, 2028Registry ↗
Dec 8, 2025Evaluation of Clinical Benefit and Safety Following CYFENDUS Administration for Post-Exposure Proph…
NCT07268612 · Anthrax
CYFENDUS
EBS
Emergent BioSolutions
—Not yet recruiting250Nov 2036Registry ↗
Sep 8, 2025Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
NCT04067011 · Anthrax
Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet
EBS
Emergent BioSolutions
Phase 2Completed210Mar 5, 2020Registry ↗
Jun 15, 2025Ciprofloxacin BioThrax Co-Administration Study
NCT01753115 · Anthrax
BioThrax, Ciprofloxacin
EBS
Emergent BioSolutions
Phase 2Completed154Aug 2013Registry ↗
Jun 8, 2025A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes t…
NCT05142306 · SARS-CoV-2 Infection
COVID-HIG
EBS
Emergent BioSolutions
Phase 1Completed23Mar 28, 2022Registry ↗
Jun 8, 2025A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adu…
NCT04661839 · COVID-19
COVID-HIGIV, Placebo (saline)
EBS
Emergent BioSolutions
Phase 1Completed28Jul 27, 2021Registry ↗
Jun 3, 2025Study of SIAN Nasal Spray in Healthy Adults
NCT05194358 · Cyanide Poisoning
Stabilized Isoamyl Nitrite (SIAN)
EBS
Emergent BioSolutions
Phase 1Completed47Sep 29, 2023Registry ↗
Jan 20, 2025Universal Influenza A Vaccine in Healthy Adults
NCT05155319 · Human Influenza
UFluA 20 µg each antigen/dose, UFluA 60 µg each antigen/dose
EBS
Emergent BioSolutions
Phase 1Completed27Oct 10, 2023Registry ↗
Jan 15, 2025Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
NCT05935917 · Smallpox
Brincidofovir
EBS
Emergent BioSolutions
Phase 1Completed44Aug 14, 2023Registry ↗
Apr 9, 2024Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in…
NCT01491607 · Anthrax
BioThrax
EBS
Emergent BioSolutions
Phase 3Completed200May 2012Registry ↗
Apr 9, 2024Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy A…
NCT00679172 · Typhoid
Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (…
EBS
Emergent BioSolutions
Phase 2Completed187Dec 2008Registry ↗
Apr 4, 2024Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
NCT00928577 · Smallpox
EBS
Emergent BioSolutions
—Completed14,108Dec 2014Registry ↗
Mar 18, 2024Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (Z…
NCT03624946 · Zika Virus Infection, Zika Virus Disease
Zika Virus Immune Globulin (ZIKV-IG), Placebo
EBS
Emergent BioSolutions
Phase 1Completed30Mar 6, 2019Registry ↗
Mar 18, 2024Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Ad…
NCT03315104 · Influenza A H3N2, Influenza A H1N1
FLU-IGIV, Placebo for FLU-IGIV
EBS
Emergent BioSolutions
Phase 2Completed65Jun 17, 2019Registry ↗
Mar 18, 2024A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
NCT03160339 · Adenoviral Infection
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
EBS
Emergent BioSolutions
Phase 1Terminated25Nov 27, 2017Registry ↗
Mar 18, 2024Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected A…
NCT02771730 · Healthy Volunteer, HIV Vaccine
Ad4-mgag, Ad4-EnvC150
EBS
Emergent BioSolutions
Phase 1Terminated20Feb 2017Registry ↗
Mar 18, 2024Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to He…
NCT02696291 · Viral Infection
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution
EBS
Emergent BioSolutions
Phase 1Terminated7Mar 2, 2017Registry ↗
Mar 18, 2024VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
NCT02443623 · Smallpox Vaccine Adverse Reaction
Vaccination with ACAM2000
EBS
Emergent BioSolutions
Phase 4Completed3,032Jul 2021Registry ↗
Mar 18, 2024Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
NCT02339155 · Infections, Bacterial
AVA, Raxibacumab
EBS
Emergent BioSolutions
Phase 4Completed573Jan 3, 2017Registry ↗
Mar 18, 2024Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Ora…
NCT02061358 · Viral Infection
UV-4B 3 mg, UV-4B 10 mg
EBS
Emergent BioSolutions
Phase 1Completed64Jul 2015Registry ↗
Mar 18, 2024A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector…
NCT01979406 · Anthrax Infection
AVA, Ad4-PA-1
EBS
Emergent BioSolutions
Phase 1Completed120Oct 2014Registry ↗
Mar 18, 2024A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Lev…
NCT01770743 · Anthrax
AV7909, BioThrax
EBS
Emergent BioSolutions
Phase 2Completed168Feb 2014Registry ↗
Mar 18, 2024Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
NCT01540929 · Smallpox
EBS
Emergent BioSolutions
—Completed5,001Sep 2012Registry ↗
Mar 18, 2024ACAM2000® Myopericarditis Registry
NCT01395082 · Myocarditis, Pericarditis
EBS
Emergent BioSolutions
—Completed24Feb 4, 2019Registry ↗
Mar 18, 2024Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
NCT01311674 · Healthy Volunteers
hepatitis B vaccine, hepatitis B vaccine
EBS
Emergent BioSolutions
Phase 3Terminated141Mar 11, 2011Registry ↗
Mar 18, 2024Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
NCT01263691 · Bacillus Anthracis (Anthrax) Infection
BioThrax, AV7909 Formulation 1
EBS
Emergent BioSolutions
Phase 1Completed105May 2012Registry ↗
Mar 18, 2024VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
NCT01158157 · Smallpox Vaccine Adverse Reaction
ACAM2000
EBS
Emergent BioSolutions
Phase 3Completed25Feb 14, 2012Registry ↗
Mar 18, 2024Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenz…
NCT01006798 · Bird Flu, Influenza
Placebo, Ad4-H5-Vtn
EBS
Emergent BioSolutions
Phase 1Completed166Sep 2011Registry ↗
Mar 18, 2024Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
NCT00927719 · Smallpox
ACAM2000® smallpox vaccine
EBS
Emergent BioSolutions
—Completed897,227Dec 31, 2017Registry ↗
Mar 18, 2024HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
NCT00877656 · T Cell Lymphoma
HuMax-CD4
EBS
Emergent BioSolutions
Phase 2/3Completed21Jan 2006Registry ↗
Mar 18, 2024Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
NCT00845650 · Anthrax
AIGIV 3.5 mg/kg, Gamunex 90 mg/kg
EBS
Emergent BioSolutions
Phase 1/2Completed129Oct 2010Registry ↗
Mar 18, 2024Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
NCT00636519 · Healthy Volunteers
Botulism Antitoxin Bivalent (Equine) Types A and B, Botulis…
EBS
Emergent BioSolutions
Phase 1Completed36Oct 2009Registry ↗
Mar 18, 2024Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
NCT00360737 · Healthy
Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)
EBS
Emergent BioSolutions
Phase 1Completed40Dec 2006Registry ↗
Mar 18, 2024Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox…
NCT00053495 · Smallpox
Vaccinia virus: ACAM2000 smallpox vaccine, vaccinia virus (…
EBS
Emergent BioSolutions
Phase 2Completed353Jun 2003Registry ↗
Mar 18, 2024Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
NCT00053482 · Smallpox
ACAM2000 Smallpox Vaccine, Vaccinia virus (calf lymph) smal…
EBS
Emergent BioSolutions
Phase 2Completed357Apr 2003Registry ↗
Mar 15, 2024BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulin…
NCT02055183 · Botulism
BAT
EBS
Emergent BioSolutions
—Completed162Jul 2017Registry ↗
Mar 15, 2024BioThrax® (Anthrax) Vaccine in Pregnancy Registry
NCT01653392 · Pregnancy Complications, Pregnancy Outcome
Observational Intervention
EBS
Emergent BioSolutions
—Completed98Feb 2020Registry ↗
Mar 15, 2024Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
NCT01202695 · Anthrax
AVP-21D9, Placebo
EBS
Emergent BioSolutions
Phase 1Completed50Jun 2011Registry ↗
Mar 15, 2024Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
NCT00448253 · Symptoms of Inhalational Anthrax
NP-015
EBS
Emergent BioSolutions
Phase 1Completed92Aug 2008Registry ↗

47 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:21 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances